Aigen Investment Management LP Takes Position in Novartis AG (NYSE:NVS)

Aigen Investment Management LP purchased a new position in shares of Novartis AG (NYSE:NVS) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 2,394 shares of the company’s stock, valued at approximately $233,000.

Other large investors have also bought and sold shares of the company. Human Investing LLC bought a new stake in shares of Novartis during the fourth quarter worth $25,000. Union Bancaire Privee UBP SA acquired a new position in Novartis during the 4th quarter worth about $27,000. Legacy Investment Solutions LLC acquired a new position in Novartis during the 3rd quarter worth about $28,000. Kestra Investment Management LLC bought a new stake in Novartis during the 4th quarter worth about $47,000. Finally, Brooklyn Investment Group acquired a new stake in Novartis in the 4th quarter valued at about $55,000. 13.12% of the stock is currently owned by institutional investors.

Novartis Trading Up 2.4 %

NYSE NVS opened at $115.60 on Monday. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The stock has a 50-day simple moving average of $104.02 and a 200 day simple moving average of $107.89. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $236.29 billion, a PE ratio of 19.66, a P/E/G ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Research analysts forecast that Novartis AG will post 8.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Barclays reiterated an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. UBS Group restated a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. Finally, Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average price target of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.